Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (9): 564-571.
Previous Articles Next Articles
NIU Yaping1, LIANG Beibei2, SUN Pai2, WANG Rui2, JIA Jinsheng3*
Received:2018-11-02
Revised:2018-11-02
Online:2018-09-20
Published:2018-11-02
CLC Number:
NIU Yaping, LIANG Beibei, SUN Pai, WANG Rui, JIA Jinsheng. Review of New Drugs with QIDP Certification Approved by FDA[J]. Chinese Journal of Pharmacovigilance, 2018, 15(9): 564-571.
| [1] Olsufyeva E N, Tevyashova A N. Synthesis, Properties,Mechanism of Action of New Generation of Polycyclic Glycopeptide Antibiotics[J]. Current Topics in Medicinal Chemistry, 2017,17(19):2166-2198. [2] Streit J M, Fritsche T R, Sader H S, et al.Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates[J]. Diagnostic Microbiology & Infectious Disease, 2004, 48(2):137-143. [3] Gales A C, Sader H S, Jones R N.Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres[J]. Clin Microbiol Infect, 2005, 11(2):95-100. [4] Goldstein E J, Citron D M, Warren Y A, et al.In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections[J]. Antimicrobial Agents & Chemotherapy, 2006, 50(8):2875-2879. [5] Smith J R, Roberts K D, Rybak M J.Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections[J]. Infectious diseases and therapy, 2015; 4(3): 245-258. [6] Dunne M W, Puttagunta S, Sprenger C R, et al.Extended-duration dosing and distribution of dalbavancin into bone and articular tissue[J]. Antimicrobial Agents & Chemotherapy, 2015, 59(4):1849-1855. [7] Cavaleri M, Riva S, Valagussa A, et al. Pharmacokinetics and excretion of dalbavancin in the rat[J]. The Journal of antimicrobial chemotherapy, 2005, 55 Suppl 2(3):ii31-ii35. [8] Johnson D M, Fritsche T R, Sader H S, et al.Evaluation of dalbavancin in combination with nine antimicrobial agents to detect enhanced or antagonistic interactions[J]. International Journal of Antimicrobial Agents, 2006, 27(6):557-560. [9] Agarwal R, Bartsch S M, Kelly B J, et al.Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: a systematic review, network meta-analysis and cost analysis[J]. Clin Microbiol Infect, 2017,24(4):361-368. [10] Boucher H W, Wilcox M, Talbot G H, et al.Once-weekly dalbavancin versus daily conventional therapy for skin infection[J]. N Engl J Med, 2014, 370(23):2169-2179. [11] Barriere S, Genter F, Spencer E, et al.Effects of a New Antibacterial, Telavancin, on Cardiac Repolarization (QTc Interval Duration) in Healthy Subjects[J]. Journal of Clinical Pharmacology, 2004, 44(7):689-695. [12] FDA.Dalvance (dalbavancin) for injection, for intravenous use: US prescribingg information[EB/OL].(2016-01-21)[2018-03-19].http://www.acc-essdata.fda.gov/drugsatfda_docs/label/2016/ 021883s003lbl. [13] Zhanel G G, Calic D, Schweizer F, et al.New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin[J]. Drugs, 2010, 70(7):859-886. [14] Schaadt R, Sweeney D, Shinabarger D, et al.In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent[J]. Antimicrob Agents Chemother, 2009, 53(8):3236-3239. [15] Prokocimer P, Bien P, Deanda C, et al.In Vitro Activity and Microbiological Efficacy of Tedizolid (TR-700) against Gram-Positive Clinical Isolates from a Phase 2 Study of Oral Tedizolid Phosphate (TR-701) in Patients with Complicated Skin and Skin Structure Infections[J]. Antimicrobial agents and chemotherapy, 2012, 56(9):4608-4613. [16] O'Riordan W, Green S, Mehra P, et al. Tedizolid Phosphate for the Management of Acute Bacterial Skin and Skin Structure Infections: Efficacy Summary[J]. Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America, 2014, 58(supp1):43-50. [17] Prokocimer P, De Anda C, Fang E, et al.Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial[J]. Jama, 2013, 309(6):559-569. [18] Brown S D, Traczewski M M.Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazo-lidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges[J]. Antimicrobial Agents & Chemotherapy, 2010, 54(5):2063-2069. [19] Locke J B, Zurenko G E, Shaw K J, et al.Tedizolid for the management of human infections: in vitro characteristics[J]. Clinical Infectious Diseases An Official Publication of the Infectious Diseases Society of America, 2014, 58(supp1):35-42. [20] Shaw K J, Poppe S, Schaadt R, et al.In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains[J]. Antimicrobial Agents & Chemotherapy, 2008, 52(12):4442-4447. [21] Locke J B, Finn J, Hilgers M, et al.Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphyloc-occus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations[J]. Antimicrobial Agents & Chemotherapy, 2010, 54(12):5337-5343. [22] Flanagan S, Minassian S L, Morris D, et al.Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment[J]. Antimicrob Agents Chemother, 2014, 58(11):6471-6416. [23] McCool R, Gould I M, Eales J, et al. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA[J]. Bmc Infectious Diseases, 2017, 17(1):39-49. [24] Prokocimer P, Bien P, Surber J, et al.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections[J]. Antimicrobial Agents & Chemotherapy, 2011, 55(2):583-592. [25] Michalska K, Karpiuk I, Krol M, et al.Recent development of potent analogues of oxazolidinone antibacterial agents[J]. Bioorganic & Medicinal Chemistry, 2013, 21(3):577-591. [26] Zhanel G G, Schweizer F, Karlowsky J A.Oritavancin: mechanism of action[J]. Clinical Infectious Diseases, 2012, 54(suppl 3): 214-219. [27] Belley A, McKay G A, Arhin F F, et al. Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing[J]. Antimicrobial Agents & Chemotherapy, 2010, 54(12):5369-5371. [28] Belley A, Harris R, Beveridge T, et al.Ultrastructural Effects of Oritavancin on Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus[J]. Antimicrobial Agents & Chemotherapy, 2009, 53(2):800-804. [29] Lin G, Pankuch G, Appelbaum P C, et al.Antistaphylococcal activity of oritavancin and its synergistic effect in combination with other antimicrobial agents[J]. Antimicrobial Agents & Chemotherapy, 2014, 58(10):6251-6254. [30] Saravolatz L D, Pawlak J, Johnson L B.In vitro activity of oritavancin against community-associated methicillin-resistant Stap-hylococcus aureus (CA-MRSA), vancomycin-intermediate S. aureus (VISA), vancomycin-resistant S. aureus (VRSA) and daptomycin-non-susceptible S. aureus (DNSSA)[J]. International Journal of Antimicrobial Agents, 2010, 36(1):69-72. [31] Mendes R E, Sader H S, Flamm R K, et al.Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide[J]. Journal of Antimicrobial Chemotherapy, 2014, 69(6):1579-1581.[32] Morrissey I, Seifert H, Canton R, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011[J]. Journal of Antimicrobial Chemotherapy, 2013, 68(1):164-167. [33] FDA. Orbactiv (oritavancin) for injection, for intravenous use: US prescribing information[EB/OL].(2016-10-18)[2018-03-19].http://www.accessdata.fda.gov/drugsatfda_docs/label/32016/ 206334s003lbl. [34] Corey G R, Good S, Jiang H, et al.Single-Dose Oritavancin Versus 7-10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure, Infections: The SOLO II Noninferiority Study[J]. Clinical Infectious Diseases, 2014, 60(2):254-262. [35] Toda A, Ohki H, Yamanaka T, et al.Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: Discovery of FR264205[J]. Bioorganic & Medicinal Chemistry Letters, 2008, 18(17):4849-4852 . [36] Drawz S M, Bonomo R A.Three Decades of β-Lactamase Inhibitors[J]. Clinical Microbiology Reviews, 2010, 23(1):160-201. [37] Toussaint K A, Gallagher J C.β-lactam/β-lactamase inhibitor combinations: from then to now[J]. Annals of Pharmacotherapy, 2014, 49(1):86-98. [38] Rice LB.Progress and challenges in implementing the research on ESKAPE pathogens[J]. Infection Control & Hospital Epidemiology, 2010, 31(1):S7-S10. [39] Takeda S, Nakai T, Wakai Y, et al.In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa[J]. Antimicrobial Agents & Chemotherapy, 2007, 51(3):826-830. [40] Walkty A, Adam H, Baxter M, et al.In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16[J]. Journal of Antimicrobial Chemotherapy, 2017, 4(Suppl 1):372-372. [41] Ge Y, Whitehouse M J, Friedland I, et al.Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions[J]. Antimicrobial Agents & Chemotherapy, 2010,54(8):3427-3431. [42] Popejoy M W, Paterson D L, Cloutier D, et al.Efficacy of ceftolozane/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials[J]. J Antimicrob Chemother, 2017,72(1):268-272. [43] Chen M, Zhang M, Huang P, et al.Novel β-lactam/β-lactamase inhibitors versus alternative antibiotics for the treatment of complicated intra-abdominal infection and complicated urinary tract infection: a meta-analysis of randomized controlled trials[J]. Expert review of anti-infective therapy, 2018,16(2):111-120. [44] Miller B, Hershberger E, Benziger D, et al.Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses[J]. Antimicrob Agents Chemother, 2012, 56(6):3086-3091. [45] Pragsam A K, Kumar D T, Doss C G P, et al. In silico and In vitro activity of ceftolozane/tazobactam against pseudomonas aeruginosa collected across Indian hospitals[J]. Indian journal of medical microbiology,2018,36(1): 127-130. [46] Leonard D A, Bonomo R A, Powers R A.Class D β-lactamases: a reappraisal after five decades[J]. Accounts of Chemical Research, 2013, 46(11):2407-2415. [47] Bonnefoy A, Dupuishamelin C, Steier V, et al.In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor[J]. J Antimicrob Chemother, 2004, 54(2):410-417. [48] Aktas Z, Kayacan C, Oncul O,et al.In vitro activity of avibactam (NXL104) in combination with betalactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae[J]. International journal of antimicrobial agents,2012,39(1):86-89. [49] Vazquez J A, Gonzalez Patzan L D, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study[J]. Current medical research and opinion,2012 28(12):1921-1931. [50] Lucasti C, Popescu I, Ramesh M K, et al.Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial[J]. Journal of Antimicrobial Chemotherapy, 2013, 68(5):1183-1192. [51] FDA. Cresemba (isavuconazonium sulfate): US prescribing informationa [EB/OL]. (2015-03-06)[2018-03-19].http://www.accessdata.fda.gov/drugsatfda_docs/lab-el/2015/207500Orig1s000lbl. [52] FDA. FDA approves new antifungal drug Cresemba[EB/OL]. (2015-03-06)[2018-03-19].http://www.fda.gov/newsevents/newsroom/pressannouncements/ ucm437106.htm. [53] Guinea J, Pelaez T, Recio S,et al.In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species[J]. Antimicrobial Agents & Chemotherapy, 2008, 52(52):1396-1400. [54] Illnait-Zaragozi M T, Martinez G F, Curfs-Breuker I, et al. In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba[J]. Antimicrobial Agents & Chemotherapy, 2008, 52(4):1580-1582. [55] Warn P A, Sharp A, Denning D W.In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp[J]. Journal of Antimicrobial Chemotherapy, 2006, 57(1):135-138. [56] Seifert H, Aurbach U, Stefanik D, et al.In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates[J]. Antimicrobial Agents & Chemotherapy, 2007, 51(5):1818-121. [57] Thompson G R, Wiederhold N P, Sutton D A, et al.In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species[J]. Journal of Antimicrobial Chemotherapy, 2009, 64(1):79-83. [58] Chowdhary A, Hagen F, Curfs-Breuker I, et al.In Vitro Activities of Eight Antifungal Drugs against a Global Collection of Genotyped Exserohilum Isolates[J]. Antimicrobial Agents & Chemotherapy, 2015, 59(10):6642-6645. [59] Pappas P G, Kauffman C A, Andes D R, et al .Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of Americas[S]. Clin Infect Dis,2016 ,62(4):e1-e50. [60] Desai A, Schmitt-Hoffmann A H, Mujais S, et al. Population Pharmacokinetics of Isavuconazole in Subjects with Mild and Moderate Hepatic Impairment[J]. Antimicrobial Agents & Chemotherapy, 2016,60(5):3025-3031. [61] Schmitt-Hoffmann A, Roos B, Spickermann J, et al.Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557[J]. Antimicrobial Agents & Chemotherapy, 2009, 53(11):4885-4890. [62] Lemaire S, Tulkens P M, Van Bambeke F.Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus[J]. Antimicrobial Agents & Chemo-therapy, 2011, 55(2):649-658. [63] Remy J M, Tow-Keogh C A, Mcconnell T S, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization[J]. Journal of Antimicrobial Chemotherapy, 2012, 67(12):2814-2820. [64] Zhanel G G, Palatnick L, Nichol K A, et al.Antimicrobial Resistance in Haemophilus influenzae and Moraxella catarrhalis Respiratory Tract Isolates: Results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002[J]. Antimicrobial Agents & Chemotherapy, 2003, 47(6):1875-1881. [65] Van Bambeke F, Glupczynski Y, Plesiat P, et al.Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy[J]. Journal of Antimicrobial Chemotherapy, 2003, 51(5):1055-1065. [66] Kocsis B, Domokos J, Szabo D.Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin[J]. Annals of Clinical Microbiology & Antimicrobials, 2016, 15(1):34-41. [67] Van Bambeke F.Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy[J]. Future Microbiology, 2015, 10(7):1111-1123. [68] 谭莉莉. 喹诺酮类抗菌药物的临床不良反应[J]. 中国药物警戒, 2013, 10(2):92-95. [69] Hoover R, Hunt T, Benedict M, et al.Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers[J]. Clinical Therapeutics, 2016, 38(1):53-65. [70] Hecker SJ, Reddy K R, Totrov M, et al.Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases[J]. Journal of Medicinal Chemistry, 2015, 58(9):3682-3692. [71] Lapuebla A, Abdallah M, Olafisoye O, et al.Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City[J]. Antimicrobial Agents & Chemotherapy, 2015, 59(8):4856-4860. [72] Livermore D M, Mushtaq S.Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae[J].Journal of Antimicrobial Chemotherapy, 2013, 68(8):1825-1831. [73] Sabet M, Tarazi Z, Rubioaparicio D, et al.Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-resistant Enterobacteriaceae in an In Vitro Hollow Fiber Model[J/OL]. Antimicrob Agents Chemother, 2018,62(2): e01969. [74] FDA. VABOMERE (meropenem and vaborbactam) for injectiona[EB/OL].(2017-08-30) [2018-03-19].http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/ 209776lbl. [75] 曾繁典. 抗生素及合成抗菌药物的滥用与危害[J].中国药物警戒,2004,1(1):25-27. |
| [1] | REN Zhao, LIU Jia, WANG Yumin, WANG Yue, XIE Qing. Pharmaceutical care of a case of carbapenem resistant Klebsiella pneumoniae bloodstream infection treated with ceftazidime/verbatan [J]. Chinese Journal of Pharmacovigilance, 2022, 19(11): 1258-1261. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
